Disease relapse post remission is a major predictor of poor outcome for patients with AML. The relapse rates range from 40% for patients with favorable cytogenetic abnormalities at diagnosis to 90% for patients with adverse cytogenetics.
Excluded were patients with a previous allogeneic transplant and recipients of syngeneic, haploidentical and cord blood grafts.
This study was coordinated by the Allogeneic Blood and Marrow Transplant Program of the Princess Margaret Cancer Centre, Toronto, Canada. Approval for the study was obtained from the Research Ethics Boards of all respective hospitals. Data from the original study were used to compare the distribution of variables and outcomes with the multicenter cohort. The collection of data focused on the three prognostic parameters previously identified in the single-center study:
6 patient age at transplant, duration of CR1, HCT-CI, as well as donor type, conditioning regimen intensity, duration of follow-up and survival status. Cytogenetics at diagnosis were not evaluated. Survival times were measured from the date of HCT until death from any cause. Survivors were censored on the date of last follow-up.
Patient characteristics were reported using descriptive statistics. Age groups were dichotomized at ⩾ 55 years, duration of CR1 at ⩾ 6 months and HCT-CI 0-3 or more. Distribution of patients into risk groups as defined by Michelis et al. 6 was documented for both the original single-center and the multicenter cohort. Contingency statistics were used to compare the distribution of patient characteristics between the two cohorts.
The main outcome variable was death due to any cause (OS). Time to event was calculated from the date of HCT to the date of death, or the last date of patients known to be alive. Univariate analysis for the influence of the previously described variables on OS was calculated using the Kaplan-Meier product-limit method and log-rank test. This included univariate analysis for stratification of patients into the three risk groups as defined by Michelis et al., 6 as follows: Group A (favorable risk) with duration of CR1 ⩾ 6 months, age at HCT o55 years and HCT-CI 0-3, Group B (intermediate risk) with duration of CR1 ⩾ 6 months, age at HCT o55 years and HCT-CI ⩾ 4 and Group C (unfavorable risk) with duration of CR1 o6 months and/or age at HCT ⩾ 55 years. P-values were two-sided and for the statistical analyses, P o 0.05 was considered to indicate a significant difference. Data analysis was performed using Statistical Analysis Software Version 9.3 (SAS Institute Inc., Cary, NC, USA).
Patient characteristics are described in Table 1 for both cohorts. Contingency statistics demonstrate no significant differences between the two cohorts concerning age, duration of CR1 group, HCT-CI, conditioning intensity and donor type. Risk groups for OS, as defined by Michelis et al. 6 did not demonstrate a significant difference in distribution between the two cohorts. The median time from relapse (post-CR1) to transplant was 4 months (range 2-15 months) for the original study cohort compared to 3.5 months (range 1-26 months) for the multicenter cohort.
As previously reported, the original single-center cohort demonstrated a significant impact of CR1 duration (HR = 2.72 for duration CR1 o6 months, 95% confidence interval (CI) = 1.52-4.85, P = 0.0004) and patient age (HR = 1.83 for age ⩾ 55, 95% CI = 1.07-3.14, P = 0.028) on OS. The HCT-CI was marginally significant (HR = 1.69 for HCT-CI ⩾ 4, 95% CI = 0.99-2.89, P = 0.05).
In the multicenter cohort, univariate analysis for OS confirmed the influence of CR1 duration (HR = 2.22 for duration CR1 o6 months, 95% CI = 1.47-3.36, P = 0.0001) and the HCT-CI (HR = 1.56 for HCT-CI ⩾ 4, 95% CI = 1.06-2.29, P = 0.02). In contrast, there was neither a significant influence of age dichotomized at 55 years (HR = 1.14, 95% CI = 0.78-1.67, P = 0.5) nor with cut-off values of ⩾ 40 years (HR = 1.16, 95% CI = 0.81-1.65, P = 0.42) or ⩾ 60 years (HR = 1.15, 95% CI = 0.71-1.87, P = 0.57). A marginal effect on OS was demonstrated for conditioning intensity (HR = 1.40 for RIC, 95% CI = 0.98-1.99, P = 0.06) and donor type (HR = 1.46 for unrelated, 95% CI = 1.02-2.08, P = 0.04).
The previously published prognostic risk stratification 6 was then applied to the multicenter cohort. A similar risk stratification of the previously described groups for OS was demonstrated for the multicenter cohort up to 2 years post HCT (65, 55 and 49% for the favorable (Group A, n = 144), intermediate (Group B, n = 24) and unfavorable risk groups (Group C, n = 98) respectively, P = 0.0001). This stratification, however, was not sustained with longer followup. The OS at 5 years was 58, 22 and 35% for the three respective risk groups (Figure 1a) .
Based on the different impact of age in both cohorts on OS, the previously published prognostic risk stratification 6 was modified for the multicenter cohort by removing age at HCT as a contributing factor. The risk groups were re-defined as follows: modified Group A: duration of CR1 ⩾ 6 months and HCT-CI 0-3, modified Group B: duration of CR1 ⩾ 6 months and HCT-CI ⩾ 4, modified Group C: duration of CR1 o6 months. This modified score was highly prognostic for OS (Po 0.0001, Figure 1b) with a 5 year OS of 53, 35 and 23% for the favorable (modified Group A, n = 188), intermediate (modified Group B, n = 40) and unfavorable (modified Group C, n = 39) risk groups respectively.
We demonstrated in a large multicenter cohort that duration of CR1 and the HCT-CI are of prognostic relevance for OS of AML patients undergoing transplant in CR2 whereas age at transplant does not seem to influence the long-term outcome. The original model stratified OS for the first 2 years after transplant, similar to the pattern seen in the original cohort, 6 yet the pattern was not sustained after 2 years. By removing age as a risk factor, a modified risk score was developed for the multicenter cohort. A favorable risk group was characterized by duration of CR1 ⩾ 6 months and HCT-CI 0-3, an intermediate risk group by duration of CR1 ⩾ 6 months and HCT-CI 43 and an unfavorable risk group of patients with a duration of CR1 o 6 months. The present study did not determine the reasons age had a different impact on the outcome of both cohorts. The effect might be due to numerical differences or heterogeneity in patient selection and management. Data collection was restricted to parameters with impact shown for the original cohort. The cytogenetic risk at diagnosis had no influence, 6 and thus was not included. This observation is consistent with other studies investigating the influence of cytogenetics on post transplant outcome for AML in CR2. 8, 9 In conclusion, duration of CR1 and the HCT-CI pre-allogeneic transplant comorbidity score are prognostic for OS in patients   100%   80%   60%   40%   0  12  24  36  48  60  84  72  96  0  12  24  36  48  60  84  72 ). OS at 5 years was 58, 22 and 35% for the favorable (Group A, n = 144), intermediate (Group B, n = 25) and unfavorable (Group C, n = 98) risk groups, respectively (P = 0.0001) (Group A: duration CR1 ⩾ 6 months, age at HCT o55 years and HCT-CI 0-3, Group B: duration CR1 ⩾ 6 months, age at HCT o 55 years and HCT-CI ⩾ 4, Group C: duration CR1 o6 months and/or age at HCT ⩾ 55 years). (b) Univariate analysis for OS of patients in the multicenter cohort, stratified by the modified prognostic risk groups. OS at 5 years was 53, 35 and 23% for the favorable (modified Group A, n = 188), intermediate (modified Group B, n = 40) and unfavorable (modified Group C, n = 39) risk groups, respectively (P o0.0001) (groups are defined as modified Group A: duration of CR1 ⩾ 6 months and HCT-CI 0-3, modified Group B: duration of CR1 ⩾ 6 months and HCT-CI ⩾ 4, modified Group C: duration of CR1 o6 months). Abbreviations: CR1 = first complete remission; HCT-CI = hematopoietic cell transplantation comorbidity index; MA = myeloablative; RIC = reducedintensity conditioning. transplanted for AML in CR2 as shown for both cohorts, and these results could be used to guide decision making concerning transplant. The impact of age on OS was different for the two cohorts, and this discrepancy requires further prospective investigation with a detailed analysis of disease-related risk factors, potential referral biases and transplant methodology.
